Boehringer Ingelheim (BI) has formed a long-term collaboration with ViraTherapeutics, an Innsbruck, Austria-based biopharmaceutical company focused on anti-cancer therapeutics, to jointly develop an oncolytic virus therapy platform and to investigate ViraTherapeutic’s lead candidate, vesicular stomatitis virus glycoprotein (VSV-GP), alone and in combination with other therapies.

ViraTherapeutics developed its technology with joint support from its lead investors, EMBL Ventures, and BI Venture Fund and will now be responsible for preclinical and clinical testing of VSV-GP in Phase I trials. Under the collaboration, BI receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development.

Source: Boehringer Ingelheim